home · filing · 0001104659-23-124182
8-K filed December 7, 2023, 6:59 PM ET
ticker HEPA
CIK 0001583771
leadership
confidence high
sentiment negative
materiality 0.75
Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%
Hepion Pharmaceuticals, Inc.
Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.
John Cavan (CFO) appointed interim CEO; Dr. Peter Wijngaard also resigns from board.
Board approves strategic restructuring to reduce operating costs by ~60%, with one-time charge of $400-$800K in Q4 2023.
Company to explore strategic alternatives including M&A, licensing, or sale; 131 patients in Phase 2b NASH trial.
Cash runway extended into Q2 2025; will add trial patients only if fully funded or strategic deal.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-12-04
Filed December 7, 2023, 6:59 PM ET
the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.
Effective 2023-12-04
Successor John Cavan
Filed December 7, 2023, 6:59 PM ET
Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.
Effective 2023-12-04
Filed December 7, 2023, 6:59 PM ET
Dr. Peter Wijngaard resigned from the Board of Directors of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Cavan was appointed as interim Chief Executive Officer at Hepion Pharmaceuticals, Inc..
Action appointed
Role interim Chief Executive Officer
Exact text from the filing
the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Robert Foster resigned as Chief Executive Officer at Hepion Pharmaceuticals, Inc..
Action resigned
Role Chief Executive Officer
Exact text from the filing
Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Peter Wijngaard resigned as Director at Hepion Pharmaceuticals, Inc..
Action resigned
Role Director
Exact text from the filing
Dr. Peter Wijngaard resigned from the Board of Directors of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-23-124182
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.